KR927003540A - 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체 - Google Patents

3-벤질리덴-1-카르바모일-2-피롤리돈 유사체 Download PDF

Info

Publication number
KR927003540A
KR927003540A KR1019920701837A KR920701837A KR927003540A KR 927003540 A KR927003540 A KR 927003540A KR 1019920701837 A KR1019920701837 A KR 1019920701837A KR 920701837 A KR920701837 A KR 920701837A KR 927003540 A KR927003540 A KR 927003540A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
compound
hydrogen
unsubstituted
Prior art date
Application number
KR1019920701837A
Other languages
English (en)
Other versions
KR0133550B1 (ko
Inventor
스스무 가마따
다께시 시오따
노부히로 하가
도시히꼬 오까다
히로꾸니 죠야마
사이찌 마쯔모또
Original Assignee
요시또시 가즈오
시오노기세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR927003540A publication Critical patent/KR927003540A/ko
Application granted granted Critical
Publication of KR0133550B1 publication Critical patent/KR0133550B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

내용 없음

Description

3-벤질리덴-1-카르바모일-2-피롤리돈 유사체
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식으로 나타내는 화합물,
    [상기식에서, R1및 R2각각은 독립적으로 수소, 알킬, 알콕시 또는 할로겐이고; R3는 수소 또는 아실이며; R4는 수소, 알킬, 히드록시, 알콕시, 시아노 또는 할로겐이고; R5및 R6각각은 독립적으로 수소, 알킬, 아릴, 아르알킬, 헤테로시클릭기, 치환 또는 비치환 아미노 또는 OR7(여기서, R7은 수소, 알킬, 아릴, 아실 또는 아르알킬이다)이거나 또는 인접한 질소 원자와 함께 N,O 및/또는 S가 포함될 수 있는 헤테로시클릭기를 형성해도 무방하며, X및 Y각각은 독립적으로 O, S 치환 또는 비치환 아미노, 또는 치환 또는 비치환 메틸렌이다].
  2. 제1항에 있어서, X 및 Y각각이 독립적으로 치환 또는 비치환 메틸렌임을 특징으로 하는 화합물.
  3. 제1항에 있어서, X가 O이고 Y는 치환 또는 비치환 메틸렌임을 특징으로 하는 화합물.
  4. 제1항에 있어서, X가 S이고 Y는 치환 또는 비치환 메틸렌임을 특징으로 하는 화합물.
  5. 제1항에 있어서, X가 치환 또는 비치환 메틸렌이고, Y는 O또는 S임을 특징으로 하는 화합물.
  6. 제1항 내지 5항중 어느 한 항에 있어서, R5가 수소이고 R6은 알킬, 히드록시, 알콕시 또는 아세톡시임을 특징으로 하는 화합물.
  7. 제l항 내지 5항중 어느 한 항에 있어서, R5가 알킬이고, R6은 알킬, 히드록시, 알콕시 또는 아세톡시임을 특징으로 하는 화합물.
  8. 제1항 내지 5항중 어느 한 항에 있어서, R5가 알킬이고, R6은 치환 또는 비치환 아민임을 특징으로하는 화합물.
  9. 제6항 내지 8항중 어느 한 항에 있어서, R1및 R2각각이 동시에 t-부틸임을 특징으로 하는 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920701837A 1991-01-21 1992-01-14 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체 KR0133550B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2161891 1991-01-21
JP91-021618 1991-01-21
PCT/JP1992/000020 WO1992012966A1 (fr) 1991-01-21 1992-01-14 Analogue de 3-benzylidene-1-carbamoyl-2-pyrrolidone

Publications (2)

Publication Number Publication Date
KR927003540A true KR927003540A (ko) 1992-12-18
KR0133550B1 KR0133550B1 (ko) 1998-04-23

Family

ID=12060040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701837A KR0133550B1 (ko) 1991-01-21 1992-01-14 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체

Country Status (12)

Country Link
US (2) US5319099A (ko)
EP (1) EP0525197B1 (ko)
JP (1) JP3108097B2 (ko)
KR (1) KR0133550B1 (ko)
AT (1) ATE157355T1 (ko)
AU (1) AU646722B2 (ko)
CA (1) CA2078790C (ko)
DE (1) DE69221794T2 (ko)
ES (1) ES2106855T3 (ko)
HU (1) HU214333B (ko)
NO (1) NO179142C (ko)
WO (1) WO1992012966A1 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675078B2 (en) * 1992-10-28 1997-01-23 Shionogi & Co., Ltd. Benzylidene derivatives
JP3507124B2 (ja) * 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP0995745B1 (en) * 1997-06-27 2005-10-19 Kaneka Corporation Heat shock factor activity inhibitors
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
IL136738A0 (en) * 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase activity using substituted heterocyclic ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
ATE345130T1 (de) * 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
JP4636486B2 (ja) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CN1318404C (zh) * 2002-02-11 2007-05-30 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
PL1889198T3 (pl) 2005-04-28 2015-04-30 Proteus Digital Health Inc System farmakologiczno-informatyczny
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CN101878031A (zh) * 2007-04-20 2010-11-03 迪赛孚尔制药有限公司 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EA201170627A1 (ru) * 2008-10-29 2011-10-31 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
MX2011004903A (es) 2008-11-10 2011-05-30 Pfizer Ltd Pirrolidinas.
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US10822315B2 (en) 2016-08-22 2020-11-03 North Carolina State University 5-benzylidene-4-oxazolidinones
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
EP4084779A1 (en) 2019-12-30 2022-11-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
CA3163053A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Amorphous kinase inhibitor formulations and methods of use thereof
EP4181387A1 (en) 2021-11-15 2023-05-17 Siemens Schweiz AG Half-step motor driver
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1472789A1 (de) * 1965-12-10 1969-01-23 Agfa Gevaert Ag Gelbe Lichthofschutz- und Filterfarbstoffe fuer photographische Materialien
US3624081A (en) * 1967-02-15 1971-11-30 Sterling Drug Inc 1-acyl-2-ethylidenepyrrol-idine-3-carboxamides
DE1932827C3 (de) * 1969-06-28 1978-10-05 Bayer Ag, 5090 Leverkusen Cycloaliphatische Imidazolidin-2-on-1-carbonsäure-amide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Herbizide
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DE2658905A1 (de) * 1976-12-24 1978-10-19 Bayer Ag Beta-lactam-antibiotica, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS5879944A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd ３，５−ジ・タ−シヤリ−・ブチルスチレン誘導体及び抗炎症、鎮痛、解熱剤並びに血小板凝集阻害剤
JPH0623194B2 (ja) * 1985-03-23 1994-03-30 鐘淵化学工業株式会社 新規ラクタム誘導体及び抗炎症剤
JPH066571B2 (ja) * 1985-05-09 1994-01-26 エーザイ株式会社 ２−ピロリドン誘導体
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents

Also Published As

Publication number Publication date
US5319099A (en) 1994-06-07
NO179142C (no) 1996-08-14
HU214333B (hu) 1998-03-02
US5319100A (en) 1994-06-07
NO179142B (no) 1996-05-06
HUT65618A (en) 1994-07-28
AU646722B2 (en) 1994-03-03
AU1163492A (en) 1992-08-27
EP0525197A4 (en) 1993-04-07
CA2078790A1 (en) 1992-07-22
ES2106855T3 (es) 1997-11-16
ATE157355T1 (de) 1997-09-15
NO923528L (no) 1992-11-12
KR0133550B1 (ko) 1998-04-23
DE69221794T2 (de) 1998-03-19
JP3108097B2 (ja) 2000-11-13
WO1992012966A1 (fr) 1992-08-06
DE69221794D1 (de) 1997-10-02
CA2078790C (en) 1998-10-06
NO923528D0 (no) 1992-09-11
HU9203304D0 (en) 1992-12-28
EP0525197A1 (en) 1993-02-03
EP0525197B1 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
KR927003540A (ko) 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체
KR960704919A (ko) 신규인 펩티드 유도체 (novel peptide derivative)
KR890005084A (ko) 퀴놀린 유도체
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR890014448A (ko) 아실페놀 유도체
KR920000892A (ko) 도막 형성용 재료
KR900018131A (ko) 이합체 에피포도필로톡신 글루코사이드 유도체
KR840008342A (ko) 모르포린 유도체의 제조방법
KR880009959A (ko) 방향족 아민 유도체
CA2188924A1 (en) Arylpiperidine and arylpiperazine derivatives and drugs containing the same
KR890003793A (ko) 3'-데메톡시에피포도필로톡신 배당체의 유도체
KR960702463A (ko) Dc-89 유도체[dc-89 derivative]
KR900701779A (ko) 옥시란유도체 및 그것을 유효성분으로 하는 제초제
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
KR830010090A (ko) 아닐린 유도체의 제조방법
KR890016006A (ko) 피롤 유도체
KR900003201A (ko) 펩티드 및 항치매제
KR940014360A (ko) 1,4-벤즈옥사진 유도체
KR870007908A (ko) 인덴류 화합물의 제조방법
KR890004994A (ko) 신규 백금 착화합물
KR920008012A (ko) 트리아졸 유도체
KR870007115A (ko) 피로글루타미드 유도체
KR830006293A (ko) 신규 폴리아자 헤테로고리 화합물의 제조방법
KR890009887A (ko) 이미다졸 유도체
FR2619810B1 (fr) Nouveaux monomeres ethyleniques polyfonctionnels

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990705

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee